There has been no assessment made of the effect of Food and Drink Federation members\u2019 compliance or non-compliance in achieving the 20% reduction in sugar content of key products contributing to children\u2019s intakes by 2020 on childhood obesity or childhood tooth decay.<\/p>
<\/p>
In \u2018Sugar reduction: The evidence for action\u2019, published in October 2015, Public Health England (PHE) undertook modelling work to estimate the potential health impact and wider economic benefits of achieving the average population intake recommendation for sugar. This modelling found that achieving this over a 10-year period would result in 4,100 premature deaths and 204,000 cases of dental caries being averted, resulting in a total cost saving to the National Health Service of £484 million.<\/p>
<\/p>
PHE encourages all businesses to achieve the reductions in sugar as set out in \u2018Childhood obesity: a plan for action\u2019. A detailed assessment of industry\u2019s progress will be published in March 2018.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-04T11:13:15.14Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-06-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Sugar"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, with reference to the oral contribution by the former Under-Secretary of State for Health on 21 March 2017, Official Report, Column 775, what assessment he has made of the effect of the Food and Drink Federation's decision not to introduce the Government's 20 per cent optional reduction in sugar content in its members' products by 2020 on his Department's policies to tackle (a) childhood obesity and (b) childhood tooth decay.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/298", "label" : {"_value" : "Biography information for Steve McCabe"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Selly Oak"} , "tablingMemberPrinted" : [{"_value" : "Steve McCabe"} ], "uin" : "2048"} , {"_about" : "http://data.parliament.uk/resources/746734", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/746734/answer", "answerText" : {"_value" : "
There is no estimate of the total number of premature deaths attributable to air pollution.<\/p>
<\/p>
The air pollution health indicator 3.01 in the Public Health Outcomes Framework estimates the fraction of adult mortality attributable to long-term exposure to PM2.5 air pollution (in local authority areas) in England. This ranges from less than 3% in the least polluted rural areas to over 7% in some London boroughs.<\/p>
<\/p>
In 2015, the average for England was 4.7%. This is equivalent to approximately 25,000 adult deaths attributable to fine particulate matter exposure (PM2.5) in England every year.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-04T14:34:48.227Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-06-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Air Pollution: Death"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what estimate his Department has made of the total number of premature deaths attributable to air pollution in the last 12 months; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"} } , "tablingMemberConstituency" : {"_value" : "Coventry South"} , "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"} ], "uin" : "1938"} , {"_about" : "http://data.parliament.uk/resources/746815", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/746815/answer", "answerText" : {"_value" : "
The Government is developing a new tobacco control plan, which will be published shortly. The plan will contain actions to reduce the prevalence of smoking during pregnancy.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-04T11:00:17.33Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-06-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Pregnancy: Smoking"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what steps the Government plans to take to ensure that smoking rates among pregnant women fall.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"} } , "tablingMemberConstituency" : {"_value" : "Colchester"} , "tablingMemberPrinted" : [{"_value" : "Will Quince"} ], "uin" : "2014"} , {"_about" : "http://data.parliament.uk/resources/746856", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/746856/answer", "answerText" : {"_value" : "
The Department Task and Finish Working Group on Brain Tumour Research is bringing together clinicians, charities, patients, and officials to discuss how, working together with research funding partners, we can address the need to increase the level and impact of research into brain tumours. The Working Group is chaired by Professor Chris Whitty, the Department's Chief Scientific Adviser. The Working Group met for the third time on 17 May, and plans to report to the Parliamentary Under Secretary of State for Health (Lord O\u2019Shaughnessy) by autumn 2017.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-04T14:10:18.633Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-06-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Brain: Tumours"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, if he will bring forward proposals to increase funding for brain tumour research over the current Parliament; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"} } , "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"} , "tablingMemberPrinted" : [{"_value" : "Martyn Day"} ], "uin" : "2093"} , {"_about" : "http://data.parliament.uk/resources/746859", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/746859/answer", "answerText" : {"_value" : "
There is currently no published guidance on minimising patients dropping out of treatment in Improving Access to Psychological Therapies services. If a service has identified high levels of patient drop out they are encouraged to conduct a local audit in to specific parts of the pathway to identify where drop out levels are high and reasons for this.<\/p>
<\/p>
Last year the National Improving Access to Psychological Therapies team provided a number of recovery workshops across the country which included presentations from services that have developed strategies to manage drop-out rates and \u2018did not attends\u2019 within Improving Access to Psychological Therapies services. These workshops were open and available to all Improving Access to Psychological Therapies services. The National Collaborating Centre for Mental Health plans to publish an Evidence Based Treatment Pathway for Common Mental Health Disorders later in the year which is expected to include guidance in this area.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-04T11:03:25.74Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-06-29", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mental Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what guidance NHS England publishes on minimising drop-outs from the Improving Access to Psychological Therapies programme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"} } , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"} , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"} ], "uin" : "2174"} , {"_about" : "http://data.parliament.uk/resources/746916", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/746916/answer", "answerText" : {"_value" : "
The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.<\/p>
<\/p>
NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:<\/p>
https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england<\/a><\/p> <\/p> The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.<\/p> <\/p> The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.<\/p> <\/p> The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.<\/p> <\/p> Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen\u2019s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "2010"}
, {"_value" : "2011"}
, {"_value" : "2012"}
, {"_value" : "2013"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-04T11:10:26.177Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "HIV Infection: Clinical Trials"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, what steps are being taken to ensure that high-risk patients are able to access the trial outside London, Manchester and Brighton.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4429", "label" : {"_value" : "Biography information for Mr William Wragg"}
}
, "tablingMemberConstituency" : {"_value" : "Hazel Grove"}
, "tablingMemberPrinted" : [{"_value" : "Mr William Wragg"}
], "uin" : "2009"}
, {"_about" : "http://data.parliament.uk/resources/746917", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/746917/answer", "answerText" : {"_value" : " The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.<\/p> <\/p> NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:<\/p> https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england<\/a><\/p> <\/p> The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.<\/p> <\/p> The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.<\/p> <\/p> The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.<\/p> <\/p> Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen\u2019s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "2009"}
, {"_value" : "2011"}
, {"_value" : "2012"}
, {"_value" : "2013"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-04T11:10:26.237Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "HIV Infection: Clinical Trials"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, when the timeline for the next steps of the trial referred to in the announcement will be published.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4429", "label" : {"_value" : "Biography information for Mr William Wragg"}
}
, "tablingMemberConstituency" : {"_value" : "Hazel Grove"}
, "tablingMemberPrinted" : [{"_value" : "Mr William Wragg"}
], "uin" : "2010"}
, {"_about" : "http://data.parliament.uk/resources/746918", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/746918/answer", "answerText" : {"_value" : " The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.<\/p> <\/p> NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:<\/p> https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england<\/a><\/p> <\/p> The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.<\/p> <\/p> The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.<\/p> <\/p> The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.<\/p> <\/p> Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen\u2019s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2017-07-04", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "2009"}
, {"_value" : "2010"}
, {"_value" : "2012"}
, {"_value" : "2013"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2017-07-04T11:10:26.3Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2017-06-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "HIV Infection: Clinical Trials"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, when the frequently asked questions document referred to in the announcement will be published.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4429", "label" : {"_value" : "Biography information for Mr William Wragg"}
}
, "tablingMemberConstituency" : {"_value" : "Hazel Grove"}
, "tablingMemberPrinted" : [{"_value" : "Mr William Wragg"}
], "uin" : "2011"}
, {"_about" : "http://data.parliament.uk/resources/746919", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/746919/answer", "answerText" : {"_value" : " The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.<\/p> <\/p> NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:<\/p>